Prosecution Insights
Last updated: July 17, 2026
Application No. 18/435,790

PETUNIA PLANTS HAVING A SPOTTED FLOWER COLOR PATTERN

Non-Final OA §Other
Filed
Feb 07, 2024
Priority
Mar 31, 2016 — provisional 62/316,271 +4 more
Examiner
DRISCOLL, LORA E BARNHART
Art Unit
3991
Tech Center
3900
Assignee
Klemm+Sohn GmbH & Co. KG
OA Round
1 (Non-Final)
32%
Grant Probability
At Risk
1-2
OA Rounds
2y 5m
Est. Remaining
52%
With Interview

Examiner Intelligence

Grants only 32% of cases
32%
Career Allowance Rate
125 granted / 396 resolved
-28.4% vs TC avg
Strong +20% interview lift
Without
With
+20.1%
Interview Lift
resolved cases with interview
Typical timeline
4y 10m
Avg Prosecution
29 currently pending
Career history
417
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
19.6%
-20.4% vs TC avg
§102
58.6%
+18.6% vs TC avg
§112
8.8%
-31.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 396 resolved cases

Office Action

§Other
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . For reissue applications filed on or after September 16, 2012, all references to 35 U.S.C. 251 and 37 CFR 1.172, 1.175, and 3.73 are to the current provisions. Status of Claims US Patent 11,266,114 issued on 3/8/22 with claims 1-19. This reissue application was filed 2/7/24 and amended claim 1 and added new claims 20-31. Claims 1-31 are pending and under examination. Reissue Oath/Declaration The reissue oath/declaration filed with this application is defective because it fails to identify at least one error which is relied upon to support the reissue application. See 37 CFR 1.175 and MPEP § 1414. Regarding a potentially correctable error, the reissue declaration submitted 2/7/24 merely states that the ’114 patent is “partly inoperative by reason of patentee claiming less than patentee had a right to claim in the patent.” This error statement is inadequate. MPEP 1414(II)(C) instructs: It is not sufficient for an oath/declaration to merely state "this application is being filed to correct errors in the patent which may be noted from the changes made in the disclosure." Rather, the oath/declaration must specifically identify an error. In addition, it is not sufficient to merely reproduce the claims with brackets and underlining and state that such will identify the error. Any error in the claims must be identified by reference to the specific claim(s) and the specific claim language wherein lies the error. Here, the declaration does not refer to any patented claims, much less to specific language wherein lies the error to be corrected. The reissue declaration also refers to a typographical error within claim 1. “[A]n error under 35 U.S.C. 251 has not been presented where the correction to the patent is one of spelling, or grammar, or a typographical, editorial or clerical error which does not cause the patent to be deemed wholly or partly inoperative or invalid . . . .” MPEP 1402. The reissue declaration does not allege or explain that the typographical error in claim 1 renders the patent invalid or inoperative as the statute defines it. As such, the correction of this typographical error cannot support a reissue application. Claim Rejections—35 U.S.C. 251 Claims 1-31 are rejected as being based upon a defective reissue declaration under 35 U.S.C. 251 as set forth above. See 37 CFR 1.175. The nature of the defects in the declaration is set forth in the discussion above in this Office action. A replacement compliant declaration is required. Double Patenting In underlying application 16/739,926, electronic terminal disclaimers were filed and approved on 10/14/21 over PP27,237; US 9,913,438; US 10,462,991; and US 10,588,288. Applicant is not required to file these terminal disclaimers in this reissue application. See MPEP 1490(VI)(B). Conclusion No claims are allowed. Maintenance Fees Applicant is reminded of the requirement to pay all applicable maintenance fees on the original patent. See MPEP 1415.01. Duty to Disclose Applicant is reminded of the continuing obligation under 37 CFR 1.178(b), to timely apprise the Office of any prior or concurrent proceeding in which Patent No. 11,266,114 is or was involved. These proceedings would include any trial before the Patent Trial and Appeal Board, interferences, reissues, reexaminations, supplemental examinations, and litigation. Applicant is further reminded of the continuing obligation under 37 CFR 1.56, to timely apprise the Office of any information which is material to patentability of the claims under consideration in this reissue application. These obligations rest with each individual associated with the filing and prosecution of this application for reissue. See also MPEP §§ 1404, 1442.01 and 1442.04. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LORA E BARNHART DRISCOLL, whose telephone number is (571)272-1928. The examiner can normally be reached M-F 7:00-4:00 p.m. ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Patricia Engle, can be reached at 571-272-6660. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Lora E Barnhart Driscoll/Patent Reexamination Specialist, Art Unit 3991 Conferees: /KSO/Patent Reexamination Specialist, Art Unit 3991 /Patricia L Engle/SPRS, Art Unit 3991
Read full office action

Prosecution Timeline

Feb 07, 2024
Application Filed
Feb 07, 2025
Response after Non-Final Action
Jun 18, 2026
Non-Final Rejection mailed — §Other (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12653839
PROTEIN PAYLOAD RELEASE
3y 1m to grant Granted Jun 16, 2026
Patent RE50880
Anti-Human OX40L Antibodies and Methods of Treatment
3y 9m to grant Granted May 05, 2026
Patent 12564188
Hydrogel Beads for Controlled Uptake and Release of Cryoprotective Agents
3y 1m to grant Granted Mar 03, 2026
Patent RE50754
COMPOSITIONS AND METHOD FOR MULTIPLEX BIOMARKER PROFILING
3y 6m to grant Granted Jan 20, 2026
Patent RE50753
RECOMBINANT ADENOVIRUSES AND USE THEREOF
3y 4m to grant Granted Jan 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
32%
Grant Probability
52%
With Interview (+20.1%)
4y 10m (~2y 5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 396 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month